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International Circumpolar Surveillance (ICS), a population-based surveillance system for 
invasive bacterial diseases, has been established in the U.S. Arctic, Northern Canada, Greenland, 
Iceland, Norway, and Finland.  Data collection began in 1999 and includes the organisms 
Streptococcus pneumoniae, Haemophilus influenzae, Neisseria meningitidis, and Groups A and 
B Streptococcus.  This report reviews the data collected for the year 2001. 
 
Data on invasive disease with the organism Streptococcus pneumoniae are collected from all 
participating countries; data on invasive disease with the remaining organisms are currently 
collected by the U.S. Arctic, Northern Canada, and, beginning with this reporting year, 
Greenland.  A total of 1,741 cases of invasive pneumococcal disease were identified in 2001.  
Overall, rates of invasive S. pneumoniae were higher in individuals less than 2 years of age, 
however, the median age of cases was greater than 40 years in all countries except N. Canada.  
Case fatality ratios ranged from 4-29%.  Race and ethnicity data are collected only in N. Canada 
and the U.S. Arctic; rates of invasive pneumococcal disease in Northern Canadian Aboriginals 
and U.S. Arctic Native populations were 60 and 25 cases per 100,000 population, respectively, 
which represents an increase in disease from 2000 in Northern Canadian Aboriginals and a 
decrease in disease in U.S. Arctic Natives.  Pneumonia and septicemia were the most common 
clinical presentations; cigarette smoking was the most common risk factor.  Vaccine status was 
reported from four countries:  Canada, Greenland, Norway, and the U.S. Arctic and ranged from 
0-36% of reported cases vaccinated.  The most common S. pneumoniae serotypes in Finland and 
the U.S. Arctic are 4 and 14; in Iceland the most common serotype is 7; and in Greenland and N. 
Canada the most common serotype is 1. 
 
Data on invasive disease with Haemophilus influenzae, Neisseria meningitidis, and Groups A 
and B Streptococcus are currently collected in Greenland, Northern Canada, and the U.S. Arctic.  
A total of 28 H. influenzae cases, 10 N. meningitidis cases, 32 Group A Strep cases, and 27 
Group B Strep cases were collected in 2001.  In general, the highest rates of disease occurred in 
N. Canada Aboriginal or Alaska Native persons less than two years of age; however in N. 
Canada the highest rates of meningococcal disease occurred in non-Aboriginals and in the U.S. 
Arctic the highest rates of invasive disease with Haemophilus influenzae occurred in the 65+ 
years of age category. 
 









Group A Strep 
n (rate*) 
Group B Strep 
n (rate*) 
Finland 658 (13) N/A N/A N/A N/A 
Greenland 7 (12) 0 (0) 3 (5) 1 (2) 3 (5) 
Iceland 50 (18) N/A N/A N/A N/A 
N. Canada 51 (40) 18 (14) 1 (1) 2 (2) 4 (3) 
Norway 872 (19) N/A N/A N/A N/A 
U.S. Arctic 103 (16) 10 (2) 6 (1) 29 (5) 20 (3) 
Total 1741 (16) 28 (4) 10 (1) 32 (4) 27 (3) 






In January, 1999, the United States and Canada began an international cooperative initiative of 
population-based surveillance for invasive Streptococcus pneumoniae by all laboratories serving 
residents of the North American Arctic.  In January, 2000, this surveillance system expanded to 
include invasive diseases with the following organisms:  Haemophilus influenzae (all types), 
Neisseria meningitidis, Group A Streptococcus, and Group B Streptococcus.  These pathogens 
were selected for ICS because rates of these diseases are elevated in indigenous peoples of the 
north, strains of these pathogens are rapidly acquiring resistance to commonly used antibiotics, 
these pathogens are routinely cultured in clinical laboratories, and clinically important serotypes 
of Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis are vaccine 
preventable in infants and adults. 
 
Denmark’s autonomous region of Greenland joined ICS in 2000, and Iceland, Norway (including 
Svalbard), and Finland joined in 2001.  To date, year 2001 data has been submitted by Finland, 
Greenland, Iceland, Northern Canada, Norway, and the U.S. Arctic (Alaska).  This report 
contains year 2001 data on all five surveillance organisms from Greenland, Northern Canada, 




The goal of ICS is to establish an integrated network of hospital and public health facilities 
throughout the Arctic countries to monitor infectious diseases of concern.  Linking public health 
facilities within the Arctic states will allow for the collection and sharing of uniform laboratory 
and epidemiological data that will describe the prevalence of infectious diseases in Arctic 
populations and assist in the formulation of prevention and control strategies. 
 
The project, initiated in 1998, focused on establishing an ICS system for diseases caused by 
Streptococcus pneumonaie.  This bacterium causes pneumonia, meningitis, and bacteremia in 
both the very young and the elderly.  Once easily treated with antibiotics, this bacterium is now 
becoming resistant to commonly used antibiotics.  This is of great concern to the public health 
community and is increasingly a target for surveillance by many countries worldwide.  A 
polysaccharide vaccine is available for use in persons two years of age and older.  In the U.S. 
Arctic, this vaccine is recommended for all those over 55 years of age.  A conjugate vaccine for 
infants has been developed and is licensed for use in the U.S., Canada, and the European Union.  
The fact that diseases caused by Streptococcus pneumonaie are already being monitored by 
many public health authorities within the Arctic states makes establishing a circumpolar 
surveillance system for this infection feasible.  In addition, due to the availability of 
polysaccharide and conjugate vaccines, much of the morbidity and mortality caused by 
Streptococcus pneumonaie is currently preventable. 
 
Key objectives of ICS include: 
  Identifying key public health contacts within Arctic countries.  These persons should be 
familiar with infectious disease surveillance systems in place (particularly surveillance 
systems for diseases caused by Streptococcus pneumoniae) in the member country.  Through 




  Determining the comparability of laboratory and data collection methods, and negotiating 
standard protocols and quality control programs. 
  Sharing and reporting data in agreed upon formats. 
  The formation of a working group of key laboratory and public health contacts to coordinate 
pneumococcal surveillance within their respective jurisdictions.  This group meets on a 
regular basis to review problems, progress, compliance, report generation, and future plans. 
  The formation of a steering committee of national Arctic health experts to coordinate new 
objectives and initiatives within ICS. 
 
This program forms a framework through which surveillance of other infectious diseases as well 
as prevention and control programs can be added.  Other infectious diseases of circumpolar 
community concern include:  other invasive bacterial diseases (caused by Haemophilus 
influenzae, Neisseria meningitidis, Groups A and B Streptococcus), tuberculosis, HIV, hepatitis, 
foodborne diseases (botulism, brucellosis), waterborne diseases, respiratory diseases of children 
such as those caused by respiratory syncytial virus, and chronic conditions related to infectious 
agents (hepatitis B virus and liver cancer, human papilloma virus, and cervical cancer).  In 
addition, the surveillance model developed by this program for infectious disease may be 
adapted to monitor other non-infectious human health priorities of community concern. 
 
METHODS  
In the U.S. Arctic and Northern Canada, laboratory, demographic and clinical data are collected 
prospectively, while in Greenland, Iceland, Norway, and Finland, summary data are collected in 
aggregate at the end of the year. 
 
Finland 
  23 district hospital laboratories participate in ICS. o Provide diagnostic microbiology services for all residents of Finland. o All invasive isolates of Sp submitted to the National Public Health Institute (KTL) 
laboratory in Oulu. 
  Antimicrobial susceptibility testing of Sp isolates was performed by agar dilution method at 
district hospital laboratories as well as the KTL laboratory. 
  Serotyping is performed at the KTL laboratory by counter-immune-electrophoresis. 
  Population estimates for 2001 were obtained from the website http://www.stat.fi 
 
Greenland 
  15 district hospital laboratories participate in ICS. o Provide diagnostic microbiology services for all residents of Greenland. o All invasive isolates of Sp, Hi, Nm, GAS, and GBS submitted to reference laboratories in 
Nuuk and Copenhagen. 
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  Antimicrobial susceptibility testing of Sp isolates was performed by agar dilution at the 
central laboratory at Queen Ingrid’s Hospital in Nuuk. 
  Serotyping was performed at the Statens Serum Institute in Copenhagen, Denmark, by the 
Quellung method. 
  Clinical and demographic data for every case of invasive Sp, Hi, Nm, GAS, and GBS was 
collected by public health authorities at the end of the year and entered onto a standardized 
collection tool, the Bacterial Diseases Surveillance Form (BDSF), which is also used in 
Iceland, Northern Canada, and the U.S. Arctic. 
  Population estimates for 2001 were obtained from the website http://www.statgreen.gl 
 
Iceland 
  10 district hospital laboratories participate in ICS. o Provide diagnostic microbiology services for all residents of Iceland. o All invasive isolates of Sp submitted to the reference hospital in Reykjavik. 
  Antimicrobial susceptibility testing of Sp isolates is performed by disc diffusion method at 
the Landspitali University Hospital (LUH) in Reykjavik and the laboratory at the regional 
hospital in Akureyri.  All oxacillin resistant isolates are then analyzed by E test. 
  Serotyping is performed at the LUH by coagglutination using antisera from Statens Serum 
Institute. 
  Clinical and demographic data for every case of invasive Sp was collected by public health 
authorities at the end of the year and entered onto the same collection form (BDSF) used in 
Greenland, Northern Canada, and the U.S. Arctic. 
  Population estimates for 2001 were obtained form the website http://www.hagstofa.is 
 
Northern Canada 
  14 Canadian laboratories participate in ICS. o Provide diagnostic microbiology services for all residents of the Yukon Territory, 
Northwest Territories, Nunavut, Northern Quebec, and Northern Laborador. o Submit all invasive isolates of Sp, Hi, Nm, GAS, and GBS to one of two reference 
laboratories in Canada. o Sp, Hi, GAS, and GBS isolates are serotyped by the Quellung method using Statens 
Serum Institute antisera. 
  Antimicrobial susceptibility of Sp, GAS, and GBS isolates was tested by micro-broth dilution 




 Communicable disease consultants located within one of the five regions of Northern Canada 
provided clinical and demographic information on the same collection form (BDSF) used in 
Greenland, Iceland, and the U.S. Arctic. 
  Laboratory and clinical data are forwarded to the ICS coordinator at AIP in Anchorage. 
  Population estimates for 2001 were obtained from the website http://www.statcan.ca 
 
Norway 
  33 district hospital laboratories participate in ICS. o Provide diagnostic microbiology services for all residents of Norway. o All invasive isolates of Sp submitted to one of two reference laboratories in Oslo or 
Tromso. 
  Antimicrobial susceptibility testing of Sp isolates is performed using the disc diffusion 
method at district hospital laboratories, the reference laboratory in Tromso or the main 
national laboratory in Oslo. 
  Serotyping is performed at the Statens Serum Institute in Denmark by the Quellung method. 
  Population estimates for 2001 were obtained from the website http://www.ssb.no 
 
U.S. Arctic 
  Population-based surveillance in the state of Alaska o Since 1980 for invasive Hi. o Since 1986 for invasive Sp. o Since 1999 for invasive diseases caused by Nm, GAS, and GBS. o Coordinated by the Arctic Investigations Program (AIP), National Center for Infectious 
Disease, Centers for Disease Control and Prevention, in Anchorage, Alaska. 
  23 laboratories providing diagnostic services to residents of Alaska submitted to AIP isolates 
of Sp, Hi, Nm, GAS, and GBS cultured in blood, cerebrospinal fluid, or from other sterile 
sites. o Sp and Hi isolates are sertoyped by the Quellung method using Statens Serum Institute 
antisera. o Serogroup testing of Nm isolates from Alaska is performed at the Canadian National 
Centre for Meningococcal Disease in the CNS Infections Laboratory in Winnipeg.  By the slide agglutination method using specific antisera.  By PCR detection of the siaDgene responsible for synthesis of the serogroup-specific 
polysialytransferase. 
  Antimicrobial susceptibility testing of Sp isolates is performed at AIP by micro-broth 




 Clinical and demographic information on each case-patient is recorded by AIP research 
nurses onto the same collection form (BDSF) used in Greenland, Iceland, and Northern 
Canada. 
  Population estimates for 2001 were obtained from the website http://www.labor.state.ak.us 
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Streptococcus pneumoniae  
Case Demographics 
 
A total of 1,741 cases of invasive disease caused by Streptococcus pneumoniae were reported to 
ICS during 2001 by Finland, Greenland, Iceland, N. Canada, Norway, and the U.S. Arctic.  The 
highest rates of disease (40 per 100,000) occurred in Northern Canada and the lowest in 
Greenland (12 per 100,000) with an overall rate for the ICS circumpolar region of 16 per 
100,000; 52% of all cases occurred in males.  Median age of cases overall was 57 years with the 
lowest median age in N. Canada (28 years) and the highest in Norway (63 years).  Case fatality 
ratios ranged from 4% in N. Canada to 29% in Greenland; the overall case fatality ratio was 9%. 
 










Finland 5,195,000 658 13 349 (53) 53 (0-94) Unknown‡ 
Greenland 56,542 7 12 5 (71) 46 (1-60) 2 (29) 
Iceland 285,054 50 18 29 (58) 41 (0-92) 6 (13)a 
N. Canada 127,870 51 40 27 (53) 28 (0-82) 2 (4)a 
Norway 4,503,436 872 19 437 (50) 63 (0-96) 72 (8) 
U.S. Arctic 633,630 103 16 50 (49) 41 (0-101) 12 (12)a 
Total 10,801,532 1,741 16 897 (52) 57 (0-101) 94 (9) 
*Number of cases per 100,000 per year 
†Case fatality ratio 
‡Case outcomes not reported from Finland 
aCase outcomes unknown in cases from Iceland (2), N. Canada (6), U.S. Arctic (1)  
Streptococcus pneumoniae Rates by Age Category, ICS 2001 Data 
Age  Finland Greenland Iceland N. Canada Norway U.S. Arctic 
<2 yrs 
Population 123,956 1,696 8,527 4,742 118,938 20,199 
Cases (%) 48 (7) 2 (29) 9 (18) 8 (16) 47 (5) 17 (17) 
Rate* 39 118 106 169 40 84.2 
2-19 yrs 
Population 1,153,494 17,310 78,389 43,873 1,049,453 191,247 
Cases (%) 54 (8) 0 (0) 8 (16) 14 (28) 52 (6) 16 (16) 
Rate* 5 0 10 32 5 8.4 
20-64 yrs 
Population 3,127,910 34,561 165,089 73,850 2,656,219 385,104 
Cases (%) 340 (52) 5 (71) 19 (38) 24 (47) 365 (42) 54 (52) 
Rate* 11 15 12 33 14 14 
65+ yrs 
Population 789,640 2,975 33,049 5,405 678,826 37,080 
Cases (%) 216 (33) 0 (0) 14 (28) 5 (10) 408 (47) 17 (16) 
Rate* 27 0 42 93 60 43 
All ages 
Population 5,195,000 56,542 285,054 127,870 4,503,436 633,630 
Cases 658 7 50 51 872 103 
Rate* 13 12 18 40 19 16 




When stratified by age, the highest rates of disease in each age category were in N. Canada.  The 
lowest rates were in Finland and Greenland; however, the total number of cases reported in 
Greenland was small and therefore rates are unstable and should be regarded only as an 
indication of relative differences.  The highest rates of disease in all countries occurred in those 
cases less than two years of age and in cases 65+ years of age, with the exception of Greenland, 




In Greenland and Iceland, the highest proportion of Streptococcus pneumoniae cases reported 
were diagnosed during July in 2001.  N. Canada showed peaks in March, August, and October.  
Finland, Norway, and the U.S. Arctic showed no distinct seasonality of invasive disease caused 




Race and ethnicity data was collected in N. Canada and the U.S. Arctic.  Rates of invasive 
pneumococcal disease were consistently higher in Aboriginal and Native populations than in 
non-Aboriginal and non-Native populations.  In N. Canada, 96% of all cases occurred in 
Aboriginal peoples.  In the U.S. Arctic, there was a higher number of non-Native cases; however, 
rates of disease were half those found in the Native cases in all age groups.   
 
Streptococcus pneumoniae Rates by Race and Age Categories, ICS 2001 Data 
Age 
(yrs) 
 N. Canada* U.S. Arctic† 
Aboriginal Non-Aboriginal Native Non-Native 
<2 Population 3,560 1,182 5,340 14,859 Cases (rate‡) 8 (225) 0 (0) 5 (94) 8 (54) 
2-19 Population 31,515 12,358 48,154 143,093 Cases (rate‡) 13 (41) 1 (8) 4 (8) 7 (5) 
20-64 Population 36,995 36,855 61,686 323,418 Cases (rate‡) 20 (54) 1 (3) 17 (28) 32 (10) 
65+ Population 3,005 2,400 6,677 30,403 Cases (rate‡) 4 (133) 0 (0) 5 (75) 11 (36) 
All 
Ages 
Population 75,075 52,795 121,857 511,773 
Cases (rate‡) 45 (60) 2 (4) 31 (25) 58 (11) 
*Race unknown in 3 cases 20-64 years, 1 case 65+ years 
†Race unknown in 4 cases <2 years, 5 cases 2-19 years, 5 cases 2-64 years 
‡Number of cases per 100,000 per year  
Clinical Presentation 
 
The most common clinical presentations associated with Streptococcus pneumoniae were 
pneumonia, bacteremia or septicemia, and meningitis.  In Finland and Iceland, the clinical 
presentation reported most often was bacteremia (95% and 96% respectively); in Greenland, it 
was meningitis (43%); in Norway, it was septicemia (44%); and in N. Canada and the U.S. 

















Pneumonia 0 (0) 2 (29) 0 (0) 41 (80) 372 (43) 66 (64) 
Septicemia 0 (0) 2 (29) 0 (0) 2 (4) 386 (44) 16 (15) 
Bacteremia 627 (95) 0 (0) 48 (96) 3 (6) 0 (0) 4 (4) 
Meningitis 31 (5) 3 (43) 1 (2) 3 (6) 72 (8) 8 (8) 
Empyema 0 (0) 0 (0) 0 (0) 2 (4) 0 (0) 0 (0) 
Cellulitis 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 3 (3) 
Necrotizing fasciitis 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (1) 
Septic arthritis 0 (0) 0 (0) 0 (0) 0 (0) 7 (1) 1 (1) 
Osteomyelitis 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (1) 
Peritonitis 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 2 (2) 
Epiglottitis 0 (0) 0 (0) 0 (0) 0 (0) 1 (<1) 0 (0) 
Other 0 (0) 0 (0) 0 (0) 0 (0) 34 (4) 2 (2) 
Unknown 0 (0) 0 (0) 1 (2) 0 (0) 0 (0) 0 (0) 




The most frequently reported medical conditions or risk factors associated with Streptococcus 
pneumoniae cases were cigarette smoking and alcohol abuse.  Cigarette smoking was reported in 
26% of cases in N. Canada, 25% of cases in the U.S. Arctic, and 14% of cases in Greenland.  
Alcohol abuse was reported in 23% of cases in the U.S. Arctic and 18% of cases in N. Canada; 
Greenland did not report alcohol abuse in any cases. 
 
Streptococcus pneumoniae Cases Risk Factor/Medical Conditions, ICS 2001 Data 






Cigarette Smoking 1 (14) 13 (26) 26 (25) 
Chronic Lung Disease and/or Asthma 0 (0) 4 (8) 20 (19) 
Alcohol Abuse 0 (0) 9 (18) 24 (23) 
Immunosuppressive Therapy 0 (0) 0 (0) 4 (4) 
Diabetes 0 (0) 3 (6) 6 (6) 
Injection Drug User 0 (0) 0 (0) 5 (5) 




In Finland, Iceland, N. Canada, Norway, and the U.S. Arctic, 23-valent pneumococcal 
polysaccharide vaccine (PS23) is recommended for persons over 55 years (U.S. Arctic), over 60 
years (Iceland) or over 65 years of age (Finland, N. Canada, Norway), and to persons greater 
than two years of age with specific medical problems.  The pneumococcal 7-valent conjugate 
vaccine (PCV7) was introduced into the infant immunization schedule in the U.S. Arctic in 
January, 2001.  Vaccine data was not reported from Finland and Iceland.  Vaccine status was 
missing from a high percentage of cases from Norway and the U.S. Arctic.  Seventeen to thirty-
six percent of Streptococcus pneumoniae cases with known vaccination status were vaccinated 
with PS23 in the U.S. Arctic and N. Canada.  Only 2% of Streptococcus pneumoniae cases with 
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known vaccination status in Norway were vaccinated with PS23 indicating less frequent use of 
this vaccine.  
 
Streptococcus pneumoniae Case Vaccination Status for Pneumococcal Vaccine, ICS 2001 Data 
 Greenland N. Canada Norway U.S. Arctic 
Total cases 7 51 872 104 
Vaccinated n (%)* 0 (0) 8 (17) 10 (2) 21 (36) 
Vaccination status missing n (%) 1 (14) 4 (8) 426 (49) 45 (43) 
*Percent of cases for which vaccine status is known (total cases – status missing cases)  
Serotypes 
 
The most prevalent Streptococcus pneumoniae serotypes reported by ICS countries in 2001 were 
1, 4, 6B, and 14, three of which are included in the 7-valent conjugate vaccine (4, 6B, 14) and all 
are included in the 23-valent pneumococcal polysaccharide vaccine.  Serotypes were not 
reported by Norway.  In the following table, yellow highlights the top four most common 
serotypes in each country.  In Greenland, only three serotypes were reported; in Iceland, 
serotypes 9, 14, and 19 were equally ranked third; and, in the U.S. Arctic, serotypes 6B and 9V 
were also equally ranked third.   
 
 Streptococcus pneumoniae Serotypes by Country, ICS 2001 Data 
Serotype Finland Greenland Iceland N. Canada U.S. Arctic 
1 14 (2) 2 (50) 0 (0) 22 (43) 5 (5) 
3 52 (8) 0 (0) 2 (4) 0 (0) 4 (4) 
4 77 (12) 0 (0) 2 (4) 6 (12) 10 (11) 
5 3 (1) 0 (0) 0 (0) 0 (0) 0 (0) 
6A 21 (3) 0 (0) 1 (2) 0 (0) 3 (3) 
6B 40 (6) 1 (25) 2 (4) 5 (10) 7 (8) 
7 1 (<1) 0 (0) 11 (22) 0 (0) 0 (0) 
7F 50 (8) 0 (0) 0 (0) 0 (0) 1 (1) 
8 18 (3) 0 (0) 1 (2) 3 (6) 3 (3) 
9 0 (0) 0 (0) 6 (12) 0 (0) 0 (0) 
9N 18 (3) 0 (0) 0 (0) 0 (0) 3 (3) 
9V 33 (5) 0 (0) 0 (0) 1 (2) 7 (8) 
10 9 (1) 0 (0) 0 (0) 0 (0) 0 (0) 
11A 7 (1) 0 (0) 0 (0) 0 (0) 4 (4) 
12 1 (<1) 0 (0) 1 (2) 0 (0) 0 (0) 
12F 22 (4) 1 (25) 0 (0) 2 (4) 6 (7) 
14 64 (10) 0 (0) 6 (12) 5 (10) 16 (17) 
14, 8 1 (<1) 0 (0) 0 (0) 0 (0) 0 (0) 
15A 4 (1) 0 (0) 0 (0) 0 (0) 1 (1) 
15B 6 (1) 0 (0) 0 (0) 0 (0) 0 (0) 
15C 5 (1) 0 (0) 0 (0) 0 (0) 0 (0) 
16 3 (1) 0 (0) 0 (0) 0 (0) 0 (0) 
17F 0 (0) 0 (0) 0 (0) 0 (0) 1 (1) 
18 1 (<1) 0 (0) 4 (8) 0 (0) 0 (0) 
18B 1 (<1) 0 (0) 0 (0) 0 (0) 0 (0) 
18C 24 (4) 0 (0) 0 (0) 2 (4) 2 (2) 
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Serotype Finland Greenland Iceland N. Canada U.S. Arctic 
19 0 (0) 0 (0) 6 (12) 0 (0) 0 (0) 
19A 21 (3) 0 (0) 0 (0) 1 (2) 2 (2) 
19F 27 (4) 0 (0) 0 (0) 0 (0) 2 (2) 
19F, 39 1 (<1) 0 (0) 0 (0) 0 (0) 0 (0) 
20 3 (1) 0 (0) 0 (0) 1 (2) 1 (1) 
22F 24 (4) 0 (0) 0 (0) 1 (2) 2 (2) 
23 0 (0) 0 (0) 8 (16) 0 (0) 0 (0) 
23A 2 (<1) 0 (0) 0 (0) 0 (0) 0 (0) 
23F 39 (6) 0 (0) 0 (0) 1 (2) 4 (4) 
29 4 (1) 0 (0) 0 (0) 0 (0) 0 (0) 
31 0 (0) 0 (0) 0 (0) 0 (0) 1 (1) 
33 12 (2) 0 (0) 0 (0) 0 (0) 0 (0) 
33F 0 (0) 0 (0) 0 (0) 0 (0) 3 (3) 
34 4 (1) 0 (0) 0 (0) 0 (0) 1 (1) 
35 2 (<1) 0 (0) 0 (0) 0 (0) 0 (0) 
35B 2 (<1) 0 (0) 0 (0) 1 (2) 0 (0) 
35F 5 (1) 0 (0) 0 (0) 0 (0) 0 (0) 
38 2 (<1) 0 (0) 0 (0) 0 (0) 0 (0) 
Non-typable 1 (<1) 0 (0) 0 (0) 0 (0) 2 (2) 
 
Vaccine-Preventable Cases and Deaths 
















Cases ≥ 2 years old with serotype in the 












Cases < 2 years old with serotype in the 












Deaths (all ages) for which the serotype 












*Number of isolates serotyped by country by age group 
†No outcome data reported by Finland 
‡Percentage of total deaths  
For the countries reporting serotype data, more than 86% of Streptococcus pneumoniae cases in 
persons ≥ 2 years of age were preventable with use of the 23-valent polysaccharide vaccine.  Use 
of the 7-valent conjugate vaccine would have potentially prevented 63-100% of Strep 
pneumoniae cases in children < 2 years of age in 2001.  In Greenland and N. Canada, 50% of 
deaths related to Streptococcus pneumoniae were potentially preventable with use of the 23-







A total of 94 deaths associated with Streptococcus pneumoniae were reported to ICS in 2001.  
Overall, the highest case fatality ratio (CFR) occurred in persons 65+ years of age (24%).  
Finland did not report outcome data.  By country, N. Canada had the highest CFR in persons 65+ 
years of age (40%) and Greenland had the highest CFR over all ages (29%).   
 
Streptococcus pneumoniae Age-Specific Case-Fatality Ratios (CFR), ICS 2001 Data 
  <2 years 2-19 years 20-64 years 65+ years All Ages 
Greenland # Cases 2 0 5 0 7 Deaths (CFR) 0 (0) 0 (0) 2 (40) 0 (0) 2 (29) 
Iceland # Cases 9 8 19 14* 50 Deaths (CFR) 1 (11) 0 (0) 1 (5) 4 (33) 6 (13) 
N. Canada # Cases 8 14* 24* 5 51 Deaths (CFR) 0 (0) 0 (0) 0 (0) 2 (40) 2 (4) 
Norway # Cases 47 52 365 408 872 Deaths (CFR) 2 (4) 2 (4) 26 (7) 42 (10) 72 (8) 
U.S. Arctic # Cases 17 16* 54 17 103 Deaths (CFR) 0 (0) 1 (7) 8 (15) 3 (18) 12 (12) 
Total # Cases 83 90* 467 444* 1,083 Deaths (CFR) 3 (4) 3 (3) 37 (8)  52 (12) 94 (9) 
*Outcome unknown in (2) N. Canada cases and (1) U.S. Arctic case 2-19 years, (4) N. Canada cases 20-64 years, 
(2) Iceland cases 65+ years  
Antimicrobial Susceptibility 
 
Streptococcus pneumoniae Penicillin Susceptibility Results, ICS 2001 Data 
 
# 
Tested S* I* I* Serotypes R* R* Serotypes 
Finland 658 631 21 † 6 † 
Greenland 3 3 0  0  
Iceland 44 41 3 6B (1), 9 (1), 19 (1) 0  
N. Canada 51 50 1 9V 0  
U.S. Arctic 91 79 7 6A (2), 6B (2), 9V (2), NT (1) 5 14 (2), 6B (2), 9V (1) 
*S=Sensitive, I=Intermediate resistance, R=Fully resistant 
†Finnish serotype data is not linked to antimicrobial susceptibility data  
In 2001, antimicrobial susceptibility results were reported to ICS from Finland, Greenland, 
Iceland, N. Canada, and the U.S. Arctic.  Of those isolates tested from the U.S. Arctic, 6% were 
fully resistant to penicillin, 8% had intermediate resistance.  The fully resistant isolates were 
serotypes 14 (40%), 6B (40%), and 9V (20%).  The isolates that showed intermediate resistance 
were serotypes 6A (29%), 6B (29%), 9V (29%), and non-typable (14.3%).  Finland submitted 
results from 658 isolates; 1% were fully resistant to penicillin and 3% had intermediate 
resistance.  The Finnish serotype data is not linked to the antimicrobial susceptibility data, so no 
comparisons can be made.  In Iceland, 7% of isolates tested had intermediate resistance to 




Full resistance to trimethoprimsulfamethoxizole (TMP-Sulfa) was found in 19% of tested 
isolates from the U.S. Arctic, 8% from N. Canada, and 14% from Iceland.  The isolates that were 
fully resistant in the U.S. Arctic were serotypes 6B (29%), 9V (18%), 14 (18%), 23F (18%), 33F 
(12%), and 6A (6%).  In N. Canada, fully resistant isolates were serotypes 1 (25%), 23F (25%), 
6B (25%), and 9V (25%).  Isolates from Iceland that were fully resistant to TMP-Sulfa were 
serotypes 19 (50%), 23 (17%), 6B (17%), and 9 (17%).  Intermediate resistance to TMP-Sulfa 
was found in 2.2% of tested isolates from the U.S. Arctic (one each serotypes 6A and 4) and 7% 
from Iceland (one each serotypes 23, 6A, and 9).   
 
Streptococcus pneumoniae TMP-Sulfa Susceptibility Results, ICS 2001 Data 
 
# 
Tested S* I* I* Serotypes R* R* Serotypes 
Iceland 43 34 3 23 (1), 6A (1), 9 (1) 6 19 (3), 23 (1), 6B (1), 9 (1) 
N. Canada 51 47 0  4 1 (1), 6B (1), 9V (1), 23F (1) 
U.S. Arctic 91 72 2 4 (1), 6A (1) 17 6A (1), 6B (5), 9V (3), 14 (3), 23F (3), 33F (2) 
*S=Sensitive, I=Intermediate resistance, R=Fully resistant  
In the U.S. Arctic, 13.2% of tested isolates were fully resistant to erythromycin and 7% from 
Iceland.  The serotypes found in the fully resistant isolates from the U.S. Arctic were 6B 
(41.7%), 14 (25%), 6A (17%), and 9V (17%).  In Iceland, the isolates that were fully resistant to 
erythromycin were serotypes 14 (67%) and 6B (33%). 
 
Streptococcus pneumoniae Erythromycin Susceptibility Results, ICS 2001 Data 
 
# 
Tested S* I* I* Serotypes R* R* Serotypes 
Iceland 42 39 0  3 14 (2), 6B (1) 
N. Canada 50 50 0  0  
U.S. Arctic 91 79 0  12 14 (3), 6A (2), 6B (5), 9V (2)  
*S=Sensitive, I=Intermediate resistance, R=Fully resistant  
Antimicrobial testing was also done for ceftriaxone, ofloxacin/levoflox, chloramphenicol, 
vancomycin, clindamycin, and rifampin.  In N. Canada, one isolate out of 50 tested (2%) showed 
intermediate resistance to ceftriaxone; all isolates tested in Greenland and Iceland were sensitive 
to ceftriaxone.  All isolates tested in N. Canada and the U.S. Arctic were sensitive to 
ofloxacin/levoflox, chloramphenicol, vancomycin, clindamycin, and rifampin.  In Iceland, two 




Haemophilus influenzae  
Case Demographics 
 
Greenland, N. Canada, and the U.S. Arctic reported the occurrence of Haemophilus influenzae in 
each country during 2001.  Greenland reported no cases and therefore will not be included in the 
results.  A total of 28 cases of invasive disease caused by Haemophilus influenzae were reported 
to ICS during 2001 by N. Canada and the U.S. Arctic.  The rate of disease was higher in N. 
Canada (14 per 100,000) than it was in the U.S. Arctic (2 per 100,000).  The percentage of males 
with disease was greater in the U.S. Arctic (70%) than in N. Canada (44%).  Median age of cases 
was higher in the U.S. Arctic (42 years) than in N. Canada (1 year).  The case fatality ratio 
(CFR) in the U.S. Arctic was twice the CFR in N. Canada.  
 










N. Canada 127,870 18 14 8 (44)‡ 1 (<1-71) 1 (9)a 
U.S. Arctic 633,630 10 2 7 (70) 42 (1-78) 2 (20) 
Total 761,500 28 4 15 (56) 2 (<1-78) 3 (14) 
*Number of cases per 100,000 per year 
†Case fatality ratio 
‡Sex unknown in (1) case from N. Canada 
aCase outcomes unknown in cases from N. Canada (7)  
When stratified by age, the highest rates of disease in each age category were in N. Canada with 
the exception of the 2-19 years age category where no cases were reported.  The highest rates of 
disease occurred in those cases less than 2 years of age and in cases 65+ years of age in both N. 
Canada and the U.S. Arctic. 
 
Haemophilus influenzae Rates by Age Category, ICS 2001 Data 
Age  N. Canada U.S. Arctic 
<2 yrs 
Population 4,742 20,199 
Cases (%) 14 (78) 1 (10) 
Rate* 295 5 
2-19 yrs 
Population 43,873 191,247 
Cases (%) 0 (0) 2 (20) 
Rate* 0 1 
20-64 yrs 
Population 73,850 385,104 
Cases (%) 3 (17) 4 (40) 
Rate* 4 1 
65+ yrs 
Population 5,405 37,080 
Cases (%) 1 (6) 3 (30) 
Rate* 19 8 
All ages  
Population 127,870 633,630 
Cases 18 10 
Rate* 14 2 





Race and ethnicity data was reported in 11 of 18 Haemophilus influenzae cases from N. Canada.  
All cases for which race is known occurred in Aboriginal populations.  Rates of disease were 
highest (281 per 100,000) in cases less than two years of age.  In the U.S. Arctic, overall rates of 
disease were twice as high in Native populations (3 per 100,000) than in non-Native populations 
(1 per 100,000); the highest rates of disease (15 per 100,000) occurred in Native individuals 65+ 
years of age. 
 
Haemophilus influenzae Rates by Race and Age Categories, ICS 2001 Data 
Age 
(yrs) 
 N Canada* US Arctic† 
Aboriginal Non-Aboriginal Native Non-Native 
<2 Population 3,560 1,182 5,340 14,859 Cases (rate‡) 10 (281) 0 (0) 0 (0) 1 (7) 
2-19 Population 31,515 12,358 48,154 143,093 Cases (rate‡) 0 (0) 0 (0) 1 (2) 0 (0) 
20-64 Population 36,995 36,855 61,686 323,418 Cases (rate‡) 1 (3) 0 (0) 1 (2) 3 (1) 
65+ Population 3,005 2,400 6,677 30,403 Cases (rate‡) 0 (0) 0 (0) 1 (15) 2 (7) 
All 
Ages 
Population 75,075 52,795 121,857 511,773 
Cases (rate‡) 11 (15) 0 (0) 3 (3) 6 (1) 
*Race unknown in 4 cases <2 years, 2 cases 20-64 years, 1 case 65+ years 
†Race unknown in 1 case 2-19 years 
‡Number of cases per 100,000 per year  
Clinical Presentation 
 
In N. Canada, the most common clinical presentation associated with Haemophilus influenzae 
was meningitis (33% of reported cases), followed by bacteremia (28%).  The most common 
clinical presentation in the U.S. Arctic was pneumonia (50% of reported cases), followed by 
septicemia (40%).  
 
Clinical Presentation of Reported Haemophilus influenzae Cases, ICS 2001 Data 




Pneumonia 3 (17) 5 (50) 
Septicemia 0 (0) 4 (40) 
Bacteremia 5 (28) 0 (0) 
Meningitis 6 (33) 0 (0) 
Empyema 1 (6) 1 (10) 
Cellulitis 1 (6) 0 (0) 
Pericarditis 1 (6) 0 (0) 
Septic arthritis 1 (6) 0 (0) 






Thirty percent of cases of Haemophilus influenzae reported in the U.S. Arctic indicated alcohol 
abuse as an associated risk factor and cigarette smoking was indicated in 20% of cases.  In N. 
Canada, 6% of cases reported alcohol abuse as a risk factor. 
 
Haemophilus influenzae Cases Risk Factor/Medical Conditions, ICS 2001 Data 




Cigarette Smoking 0 (0) 2 (20) 
Chronic Lung Disease and/or Asthma 0 (0) 1 (10) 
Alcohol Abuse 1 (6) 3 (30) 
Immunosuppressive Therapy 0 (0) 1 (10) 
Diabetes 0 (0) 0 (0) 
Injection Drug User 0 (0) 0 (0) 




The Haemophilus influenzae type b (Hib) conjugate vaccine is required as part of routine 
childhood vaccination in N. Canada and the U.S. Arctic.  Two cases of Hib were reported in N. 
Canada and one in the U.S. Arctic.  Both cases in N. Canada had received one dose of Hib 
conjugate vaccine; vaccine status for the one case in the U.S. Arctic was unknown. 
 
Haemophilus influenzae Case Vaccination Status for Hib Vaccine, ICS 2001 Data 
 N. Canada U.S. Arctic 
Total Hi cases (all serotypes) 18 10 
Vaccinated n (%)* 7 (88) 3 (75) 
Vaccination status missing n (%) 10 (56) 6 (60) 
Total Hib cases 2 1 
Vaccinated (Hib) n (%)* 2 (100) Unknown 
*Percent of cases for which vaccine status is known (total cases – status missing cases)  
Serotypes 
 
Haemophilus influenzae Serotypes by Country, ICS 2001 Data 
Serotype N. Canada U.S. Arctic 
A 9 (56) 0 (0) 
B 2 (13) 1 (10) 
D 0 (0) 2 (20) 
F 0 (0) 3 (30) 
Non-typable 5 (31) 4 (40) 
Total 16* 10 
*Of 18 Hi cases in N. Canada, 16 were serotyped  
The most common Haemophilus influenzae serotypes in N. Canada were type A (56% of  
reported cases) and the non-typables (31%).  In the U.S. Arctic, the most common serotypes 






Three deaths associated with Haemophilus influenzae were reported to ICS in 2001; one death 
occurred in N. Canada and two in the U.S. Arctic for an overall case fatality ratio (CFR) of 6% 
and 20% respectively.  The highest CFR in both countries occurred in cases that were 65+ years 
of age, 100% in N. Canada and 33% in the U.S. Arctic.  In two of the deaths, the serotypes were 
non-typable; in one death in the U.S. Arctic, the serotype was type D.   
 
Haemophilus influenzae Age-Specific Case-Fatality Ratios (CFR), ICS 2001 Data 
 N. Canada U.S. Arctic 
Age (yrs) Cases Deaths (CFR) Cases Deaths (CFR) 
<2 14 0* (0) 1 0 (0) 
2-19 0 0 (0) 2 0 (0) 
20-64 3  0 * (0) 4 1† (25) 
65+ 1 1† (100) 3 1† (33) 
All Ages 18 1 (6) 10 2 (20) 
*Outcome unknown in (5) N. Canada cases <2 years, (2) N. Canada cases 20-64 years 
†Serotype in N. Canada death non-typable; serotypes in U.S. Arctic deaths, 20-64 years 
 non-typable, 65+ years type D  
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Neisseria meningitidis  
Case Demographics 
 
Greenland, N. Canada and the U.S. Arctic reported the occurrence of Neisseria meningitidis in 
each country during 2001.  A total of 10 cases of invasive disease caused by Neisseria 
meningitidis were reported to ICS.  The rate of disease was highest in Greenland (5 per 100,000) 
and similar in N. Canada (1 per 100,000) and the U.S. Arctic (1 per 100,000).  Median age of 
cases was higher in the U.S. Arctic (37 years) than in Greenland (9 years) and N. Canada (1 year 
in one case).  No deaths were reported associated with Neisseria meningitidis in 2001. 
 










Greenland 56,542 3 5 2 (67) 9 (2-13) 0 (0) 
N. Canada 127,870 1 1 1 (100) 1 case – 1 0 (0) 
U.S. Arctic 633,630 6 1 2 (33) 37 (1-90) 0‡(0) 
Total 818,042 10 1 5 (50)  11 (1-90) 0 (0) 
*Number of cases per 100,000 per year 
†Case fatality ratio 
‡Case outcome unknown in 1 case from U.S. Arctic  
When stratified by age, the highest rates of disease occurred in cases less than two years of age 
in each country.  In those cases less than two years of age, the highest rates occurred in 
Greenland, 59 cases per 100,000.   
 
Neisseria meningitidis Rates by Age Category, ICS 2001 Data 
Age  Greenland N. Canada U.S. Arctic 
<2 yrs 
Population 1,696 4,742 20,199 
Cases (%) 1 (33) 1 (100) 1 (17) 
Rate* 59 21 5 
2-19 yrs 
Population 17,310 43,873 191,247 
Cases (%) 2 (67) 0 (0) 1 (17) 
Rate* 12 0 1 
20-64 yrs 
Population 34,561 73,850 385,104 
Cases (%) 0 (0) 0 (0) 3 (50) 
Rate* 0 0 1 
65+ yrs 
Population 2,975 5,405 37,080 
Cases (%) 0 (0) 0 (0) 1 (17) 
Rate* 0 0 3 
All ages  
Population 56,542 127,870 633,630 
Total Cases 3 1 6 
Rate* 5 1 1 





Race and ethnicity data were collected in N. Canada and the U.S. Arctic.  Overall rates of disease 
were higher in the non-Aboriginal (1.9 per 100,000) and non-Native (0.97 per 100,000) 
populations than in Aboriginal (0 per 100,000) and Native (0.8 per 100,000) populations.  
However, the highest rate of disease in the U.S. Arctic by age category occurred in Native cases 
less than two years of age (18.7 per 100,000).  The highest rate of disease in N. Canada also 
occurred in the less than two years of age category (84.6 per 100,000), but in the non-Aboriginal 
population. 
 
Neisseria menigitidis Rates by Race and Age Categories, ICS 2001 Data 
Age 
(yrs) 
 N. Canada U.S. Arctic 
Aboriginal Non-Aboriginal Native Non-Native 
<2 Population 3,560 1,182 5,340 14,859 Cases (rate*) 0 (0) 1 (85) 1 (19) 0 (0) 
2-19 Population 31,515 12,358 48,154 143,093 Cases (rate*) 0 (0) 0 (0) 0 (0) 1 (1) 
20-64 Population 36,995 36,855 61,686 323,418 Cases (rate*) 0 (0) 0 (0) 0 (0) 3 (1) 
65+ Population 3,005 2,400 6,677 30,403 Cases (rate*) 0 (0) 0 (0) 0 (0) 1 (3) 
All 
Ages 
Population 75,075 52,795 121,857 511,773 
Cases (rate*) 0 (0) 1 (2) 1 (1) 5 (1) 
*Number of cases per 100,000 per year  
Clinical Presentation 
 
All Neisseria meningitidis cases in Greenland and N. Canada presented clinically as meningitis.  
In the U.S. Arctic, the most common clinical presentation was septicemia (50% of cases) 
followed by meningitis (33%). 
 







Pneumonia 0 (0) 0 (0) 1 (16.7) 
Septicemia 0 (0) 0 (0) 3 (50) 
Meningitis 3 (100) 1 (100) 2 (33.3) 




Neither Greenland nor Canada reported any risk factors or other medical conditions associated 
with cases of Neisseria meningitidis.  In the U.S. Arctic, asplenia was reported in association 




Group A Streptococcus  
Case Demographics 
 
Greenland, N. Canada, and the U.S. Arctic reported the occurrence of Group A Streptococcus in 
each country during 2001.  A total of 32 cases of invasive disease caused by Group A 
Streptococcus were reported to ICS.  The rate of disease was highest in the U.S. Arctic (5 per 
100,000) and similar in Greenland (2 per 100,000) and N. Canada (2 per 100,000).  Overall, the 
incidence of disease was slightly higher in males (63%) than in females.  Median age of cases 
was higher in the U.S. Arctic (45 years) than in N. Canada (1 year).  Four deaths were associated 
with Group A Streptococcus, one case in Greenland and three cases in the U.S. Arctic. 
 










Greenland 56,542 1 2 1 (100) 1 case – 64 1 (100) 
N. Canada 127,870 2 2 1 (50) 1 (0.91-0.94) 0 (0) 
U.S. Arctic 633,630 29 5 18 (62) 47 (<1-83) 3 (10) 
Total 818,042 32 4 20 (63) 45 (<1-83) 4 (13) 
*Number of cases per 100,000 per year 
†Case fatality ratio  
When stratified by age, the highest rates of disease occurred in cases less than two years of age 
in N. Canada (42 per 100,000) and the U.S. Arctic (15 per 100,000).  High rates of disease also 
occurred in cases 65+ years of age in the U.S. Arctic (11 per 100,000).  
 
Group A Streptococcus Rates by Age Category, ICS 2001 Data 
Age  Greenland N. Canada U.S. Arctic 
<2 yrs 
Population 1,696 4,742 20,199 
Cases (%) 0 (0) 2 (100) 3 (10) 
Rate* 0 42 15 
2-19 yrs 
Population 17,310 43,873 191,247 
Cases (%) 0 (0) 0 (0) 1 (3) 
Rate* 0 0 1 
20-64 yrs 
Population 34,561 73,850 385,104 
Cases (%) 1 (100) 0 (0) 21 (72) 
Rate* 3 0 6 
65+ yrs 
Population 2,975 5,405 37,080 
Cases (%) 0 (0) 0 (0) 4 (14) 
Rate* 0 0 11 
All ages  
Population 56,542 127,870 633,630 
Total Cases 1 2 29 
Rate* 2 2 5 





Race and ethnicity data were collected by N. Canada and the U.S. Arctic.  Rates of disease were 
higher in the Aboriginal and Native populations than in the non-Aboriginal and non-Native 
populations.  All of N. Canada’s Group A Streptococcus disease occurred in Aboriginals under 
the age of two for a rate of 56 per 100,000.  In the U.S. Arctic, the highest rates of disease 
occurred in Natives under the age of two (38 per 100,000).   
 
Group A Streptococcus Rates by Race and Age Categories, ICS 2001 Data 
Age 
(yrs) 
 N. Canada U.S. Arctic* 
Aboriginal Non-Aboriginal Native Non-Native 
<2 Population 3,560 1,182 5,340 14,859 Cases (rate†) 2 (56) 0 (0) 2 (38) 1 (7) 
2-19 Population 31,515 12,358 48,154 143,093 Cases (rate†) 0 (0) 0 (0) 1 (2) 0 (0) 
20-64 Population 36,995 36,855 61,686 323,418 Cases (rate†) 0 (0) 0 (0) 8 (13) 12 (4) 
65+ Population 3,005 2,400 6,677 30,403 Cases (rate†) 0 (0) 0 (0) 1 (15) 3 (10) 
All 
Ages 
Population 75,075 52,795 121,857 511,773 
Cases (rate†) 2 (3) 0 (0) 12 (10) 16 (3) 
*Race unknown in 1 case 20-64 years 
†Number of cases per 100,000 per year  
Clinical Presentation 
 
In the U.S. Arctic, 41% of Group A Streptococcus cases presented clinically with septicemia; 
28% presented with cellulitis.  One of the cases in N. Canada presented with septicemia, the 
other with empyema.  The single case in Greenland presented with meningitis. 
 







Pneumonia 0 (0) 0 (0) 3 (10) 
Septicemia 0 (0) 1 (50) 12 (41) 
Meningitis 1 (100) 0 (0) 1 (3) 
Empyema 0 (0) 1 (50) 2 (7) 
Cellulitis 0 (0) 0 (0) 8 (28) 
Necrotizing fasciitis 0 (0) 0 (0) 2 (7) 
Epiglottitis 0 (0) 0 (0) 1 (3) 




Greenland and N. Canada reported no associated risk factors or medical conditions with cases of 
Group A Streptococcus in 2001.  In the U.S. Arctic, cigarette smoking and alcohol abuse were 






Four deaths in cases with Group A Streptococcus were reported to ICS in 2001.  No deaths were 
reported in N. Canada, one death was reported in Greenland, and 3 deaths were reported in the 




Group B Streptococcus  
Case Demographics 
 
Greenland, N. Canada, and the U.S. Arctic reported the occurrence of Group B Streptococcus in 
each country during 2001.  A total of 27 cases of invasive disease caused by Group B 
Streptococcus were reported to ICS.  The rate of disease was highest in Greenland (5 per 
100,000) and similar in N. Canada (3 per 100,000) and the U.S. Arctic (3 per 100,000).  The 
percentage of males with disease was higher in Greenland (67%) and the U.S. Arctic (65%) than 
in N. Canada where all disease occurred in females.  Median age of cases was also higher in 
Greenland (67 years) and the U.S. Arctic (45 years) than in N. Canada (20 years).  Three deaths 
were reported associated with Group B Streptococcus in 2001; two in Greenland and one in the 
U.S. Arctic. 
 










Greenland 56,542 3 5 2 (67) 67 (61-84) 2 (100)‡ 
N. Canada 127,870 4 3 0 (0) 20 (0-41) 0 (0) 
U.S. Arctic 633,630 20 3 13 (65) 45 (0-86) 1 (5) 
Total 818,042 27 3 15 (56) 45 (0-86) 3 (12) 
*Number of cases per 100,000 per year 
†Case fatality ratio 
‡Case outcome unknown in 1 case  
When stratified by age, the highest rates of disease occurred in cases less than two years of age 
in N. Canada (42 per 100,000) and the U.S. Arctic (15 per 100,000).  In Greenland, two of three 
cases occurred in the 65+ age category (67 per 100,000). 
 
Group B Streptococcus Rates by Age Category, ICS 2001 Data 
Age  Greenland N. Canada U.S. Arctic 
<2 yrs 
Population 1,696 4,742 20,199 
Cases (%) 0 (0) 2 (50) 3 (15) 
Rate* 0 42.2 14.9 
2-19 yrs 
Population 17,310 43,873 191,247 
Cases (%) 0 (0) 0 (0) 1 (5) 
Rate* 0 0 0.5 
20-64 yrs 
Population 34,561 73,850 385,104 
Cases (%) 1 (33.3) 2 (50) 14 (70) 
Rate* 2.9 2.7 3.6 
65+ yrs 
Population 2,975 5,405 37,080 
Cases (%) 2 (66.7) 0 (0) 2 (10) 
Rate* 67.2 0 5.4 
All ages  
Population 56,542 127,870 633,630 
Total Cases 3 4 20 
Rate* 5.3 3.1 3.2 





Race and ethnicity data was collected in N. Canada and the U.S. Arctic.  Overall rates of disease 
were higher in Aboriginal and Native populations than in non-Aboriginal and non-Native 
populations.  The highest rates of disease occurred in N. Canada Aboriginal and Alaska Native 
cases less than two years of age, 28 and 56 per 100,000 respectively. 
 
Group B Streptococcus Rates by Race and Age Categories, ICS 2001 Data 
Age 
(yrs) 
 N. Canada* U.S. Arctic 
Aboriginal Non-Aboriginal Native Non-Native 
<2 Population 3,560 1,182 5,340 14,859 Cases (rate†) 1 (28) 0 (0) 3 (56) 0 (0) 
2-19 Population 31,515 12,358 48,154 143,093 Cases (rate†) 0 (0) 0 (0) 1 (2) 0 (0) 
20-64 Population 36,995 36,855 61,686 323,418 Cases (rate†) 1 (3) 1 (3) 3 (5) 11 (3) 
65+ Population 3,005 2,400 6,677 30,403 Cases (rate†) 0 (0) 0 (0) 1 (15) 1 (3) 
All 
Ages 
Population 75,075 52,795 121,857 511,773 
Cases (rate†) 2 (3) 1 (2) 8 (7) 12 (2) 
*Race unknown in 1 case <2 years 
†Number of cases per 100,000 per year  
Clinical Presentation 
 
In Greenland and the U.S. Arctic, septicemia was the most common clinical presentation, 67% 
and 40% respectively, reported for cases of Group B Streptococcus in 2001.  Fifty percent of 
cases in Canada presented with meningitis. 
 







Pneumonia 0 (0) 0 (0) 4 (20) 
Septicemia 2 (67) 1 (25) 8 (40) 
Meningitis 1 (33) 2 (50) 1 (5) 
Peritonitis 0 (0) 0 (0) 1 (5) 
Cellulitis 0 (0) 0 (0) 3 (15) 
Amnionitis 0 (0) 0 (0) 1 (5) 
Osteomyelitis 0 (0) 0 (0) 2 (10) 
Septic Arthritis 0 (0) 1 (25) 0 (0) 




N. Canada reported no associated risk factors or medical conditions with cases of Group B 
Streptococcus in 2001.  In Greenland and the U.S. Arctic, cigarette smoking and alcohol abuse 
were reported in 33% and 40% of cases respectively.  Diabetes was reported in 25% of cases in 






Three deaths in cases with Group B Streptococcus were reported to ICS in 2001.  No deaths were 
reported in N. Canada, two deaths were reported in Greenland, and 1 death was reported in the 
U.S. Arctic (CFR 5%).  The two deaths in Greenland occurred in the 20-64 and 65+ age 
categories; the death in the U.S. Arctic was in the less than two year old age category. 
 
Group B Streptococcus Age-Specific Case-Fatality Ratios (CFR), ICS 2001 Data 
 Greenland N. Canada U.S. Arctic 
Age (yrs) Cases Deaths (CFR) Cases Deaths (CFR) Cases Deaths (CFR) 
<2 0 0 (0) 2 0 (0) 3 1 (33) 
2-19 0 0 (0) 0 0 (0) 1 0 (0) 
20-64 1 1 (100) 2 0 (0) 14 0 (0) 
65+ 2* 1 (50) 0 0 (0) 2 0 (0) 
All Ages 3* 2 (67) 4 0 (0) 20 1 (5) 
*Case outcome unknown in 1 case  
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QUALITY CONTROL  
Currently 37 clinical laboratories in the U.S. Arctic and N. Canada forward isolates from patients 
with invasive pneumococcal disease to reference laboratories in Alaska and Canada respectively.  
To ensure inter-laboratory comparability of Streptococcus pneumoniae serotyping and 
antimicrobial susceptibility testing between two reference laboratories in Canada (Alberta and 
Quebec) and one in the U.S. (Alaska), the ICS Streptococcus pneumoniae inter-laboratory 
quality control (QC) program was established in 1999. 
 
Each reference laboratory is responsible for exporting one QC panel of seven Streptococcus 
pneumoniae isolates each year to each of the other laboratories using a transportation medium of 
their choice for a total of 21 Strep pneumoniae isolates per year.  Serotyping was performed by 
Quellung reaction.  Minimum inhibitory concentration (MIC) is determined for each QC isolate 
and for ATCC strain 49619 for those antibiotics which are routinely tested in each laboratory.  
MIC results for each laboratory are expected to be within one log2 dilution of each other regardless of testing method.  Discrepancies of results are documented and examined to 
determine causes and solutions. 
 
In 2001, three QC panels of seven Streptococcus pneumoniae isolates each were shipped and 
tested by all three reference laboratories.  Serotyping correlation for 20 isolates was 100%; one 
isolate was not included in the results as it was found to be non-typable.  Overall correlation of 
the MIC results within +/- one log2 dilution was 94.9%.  MIC discrepancies between laboratories could be explained by differing ranges of antibiotic concentrations for each drug tested.  Delays 
encountered during shipment of two of the panels have prompted labs to consider using charcoal 
culturettes or to lyophilize the cultures for future shipments. 
 
CONCLUSIONS  
The ICS program continued to expand in 2001.  In addition to collecting Streptococcus 
pneumoniae data from six Arctic countries, Greenland has joined N. Canada and the U.S. Arctic 
in reporting invasive bacterial disease caused by Hi, Nm, GAS and GBS.  Monitoring rates of 
disease and levels of antimicrobial resistance in these pathogens via use of the ICS system is 
important, and efforts to expand ICS to include all circumpolar nations will continue. 
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National Public Health Institute (KTL) Laboratory, Oulu 
Laboratories Et.-Pohjanmaan sh-piiri, Seinäjoen sairaalan mikrobiol. lab. Etelä-Karjalan keskussairaalan kl.mikrobiologian laboratorio 
HY – Serobakteriologian laitos 
Jorvin sairaala, kliinisen mikrobiologian laboratorio 
KYS – Mikrobiologian laboratorio 
Kainuun keskussairaalan mikrobiologian laboratorio 
Kanta-Hämeen keskussairaalan mikrobiologian laboratorio 
Keski-Pohjanmaan keskussairaalan mikrobiologian laboratorio 
Keski-Suomen keskussairaalan mikrobiologian laboratorio 
Kymenlaakson keskussairaalan mikrobiologian laboratorio 
Lapin keskussairaalan mikrobiologian laboratorio 
Länsi-Pohjan keskussairaalan laboratorio 
Mikkelin keskussairaalan mikrobiologian laboratorio 
OYKS – Mikrobiologian laboratorio 
Oulun kiakonissalairoksen laboratorio 
Pohjois-Karjalan keskussairaalan mikrobiologian laboratorio 
Päijät-Hämeen keskussairaalan mikrobiologian laboratorio 
Rauman aluesairaalan laboratorio 
Satakunnan keskussairaalan mikrobiologian laboratorio 
Savonlinnan keskussairaalan laboratorio 
TAYS – Mikrobiologian laboratorio 
TYKS – Mikrobiologian laboratorio 





Statens Serum Institute, Copenhagen, Denmark 
Centralab at Queen Ingrid’s Hospital, Nuuk, Greenland 




















Department of Microbiology, Landspitali University Hospital, 
Reykjavik 
Laboratories Akranes Hospital Isafjordur District Hospital 
Stykkisholmur Local Health Center 
St. Joseph’s Hospital Hafnarfjorour 
Municipal Hospital of Vestmannaeyjar 
Akureyri 
Egilstadir Health Center 
Selfoss Health Center 
Sudurnes Health Center (Keflavik) 




for Disease Control 
Respiratory Division, Bureau of Infectious Diseases, Laboratory 
Centre for Disease Control, Ottawa 
Reference 
Laboratories 
National Centre for Streptococcus, Provincial Laboratory of Public 
Health, Edmonton, AB 
Laboratoire de Santé Publique du Québec, Montréal, QC 
National Centre for Meningococcus, Provincial Laboratory of Public 
Health, Winnipeg, MB 
Laboratories Whitehorse General Hospital, Whitehorse, YK Stanton Regional Health Board, Yellowknife, NT 
H.H. Williams Memorial Hospital, Hay River, NT 
Inuvik Regional Hospital, Inuvik, NT 
Baffin Regional Hospital, Iqaluit, NU 
Churchill Regional Health Authority, Churchill, MB 
Cadham Provincial Laboratory, Winnipeg, MB 
Ungava Tulattavik Health Centre, Kuujjuaq, QC 
Inulitsavik Hospital, Puvirnituq, QC 
Cree Health Board, Chisasibi, QC 
CSSSR, Chibougamou, QC 
Val d’Or Hospital, Val d’Or, QC 
Melville Hospital, Goose Bay, NL 
Newfoundland Public Health Laboratory, St. John’s, NL 
Public Health Yukon Communicable Disease Control, Whitehorse, YK Health Protection Unit, Government of NWT, Yellowknife, NT 
JA Hildes Northern Medical Unit, Winnipeg, MB 
Régie Régionale de la Santé et des Services Sociaux, Kuujjuaq, QC 
Région Cri de la Baie James, Module de Santé Publique, Montreal, 
QC 
Communicable Disease Control, Health Laborador Corporation, 
Goose Bay, NL 









Laboratories Frederikstad, Østf. SSH Sarpsborg SH 
Akershus SSH, SiA 
Bœrum SH 
Aker SH 
Fürsts laborat, Oslo 






Ullevål SH, mik.lab. 
Lab. klin. mikrob. Oslo 
Lillehammer mik.lab 
Elverum mik.lab. 
Buskerud SSH, mik.lab. 
Vestfold SSH, mik.lab. 
Telelab 
Vest-Agder SSH, mik.lab. 
Rogaland SSH, mik.lab. 
Haukeland SH, mik.lab. 
Sogn-Fk. SSH, mik.lab. 
Ålesund FSH, mik.lab. 
Molde FSH, mik.lab. 
Trondheim RSH, mik.lab. 
Innherred SH, mik.lab. 
Namdal SH, mik.lab. 
Nordland SSH, mik.lab. 
Tromsø RSH, mik.lab. 









Arctic Investigations Program, National Center for Infectious 
Diseases, Centers for Disease Control and Prevention, Anchorage, AK 
Laboratories Alaska Native Medical Center, Anchorage, AK Alaska Regional Hospital, Anchorage, AK 
Bartlett Regional Hospital, Juneau, AK 
Bassett Army Hospital, Fort Wainwright, AK 
Central Peninsula General Hospital, Soldotna, AK 
Cordova Community Medical Center, Cordova, AK 
Elmendorf Air Force Base Hospital, Anchorage, AK 
Fairbanks Memorial Hospital, Fairbanks, AK 
Kanakanak Hospital, Dillingham, AK 
Ketchikan Regional Hospital, Ketchikan, AK 
Manilaq Medical Center, Kotzebue, AK 
Norton Sound Regional Hospital, Nome, AK 
Petersburg Medical Center, Petersburg, AK 
Providence Alaska Medical Center, Anchorage, AK 
Providence Island Medical Center, Kodiak, AK 
Samuel Simmonds Memorial Hospital, Barrow, AK 
Sitka Community Hospital, Sitka, AK 
South Peninsula Hospital, Homer, AK 
Southeast Area Regional Health Corporation, Sitka, AK 
State Public Health Laboratory, Division of Public Health, 
Department of Health and Social Services, Anchorage, AK 
Valdez Community Hospital, Valdez, AK 
Valley Hospital, Palmer, AK 
Wrangell General Hospital, Wrangell, AK 
Yukon-Kuskokwim Delta Regional Hospital, Bethel, AK 
 
